179 related articles for article (PubMed ID: 24749891)
1. Treatment of gastroesophageal reflux disease: two new oral formulations dexlansoprazole MR and esomezol (esomeprazole strontium).
Parekh PJ; Oldfield EC; Johnson DA
Expert Opin Pharmacother; 2014 Jun; 15(9):1215-22. PubMed ID: 24749891
[TBL] [Abstract][Full Text] [Related]
2. Clinical efficacy of 60-mg dexlansoprazole and 40-mg esomeprazole after 24 weeks for the on-demand treatment of gastroesophageal reflux disease grades A and B: a prospective randomized trial.
Chiang HH; Wu DC; Hsu PI; Kuo CH; Tai WC; Yang SC; Wu KL; Yao CC; Tsai CE; Liang CM; Wang YK; Wang JW; Huang CF; Chuah SK;
Drug Des Devel Ther; 2019; 13():1347-1356. PubMed ID: 31118571
[No Abstract] [Full Text] [Related]
3. First-week clinical responses to dexlansoprazole 60 mg and esomeprazole 40 mg for the treatment of grades A and B gastroesophageal reflux disease.
Liang CM; Kuo MT; Hsu PI; Kuo CH; Tai WC; Yang SC; Wu KL; Wang HM; Yao CC; Tsai CE; Wang YK; Wang JW; Huang CF; Wu DC; Chuah SK;
World J Gastroenterol; 2017 Dec; 23(47):8395-8404. PubMed ID: 29307999
[TBL] [Abstract][Full Text] [Related]
4. Indirect comparison of randomised controlled trials: comparative efficacy of dexlansoprazole vs. esomeprazole in the treatment of gastro-oesophageal reflux disease.
Wu MS; Tan SC; Xiong T
Aliment Pharmacol Ther; 2013 Jul; 38(2):190-201. PubMed ID: 23718547
[TBL] [Abstract][Full Text] [Related]
5. Esomeprazole FDA Approval in Children With GERD: Exposure-Matching and Exposure-Response.
Earp JC; Mehrotra N; Peters KE; Fiorentino RP; Griebel D; Lee SC; Mulberg A; Röhss K; Sandström M; Taylor A; Tornøe CW; Wynn EL; Van der Walt JS; Garnett C
J Pediatr Gastroenterol Nutr; 2017 Sep; 65(3):272-277. PubMed ID: 27875488
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and pharmacodynamics of a known active PPI with a novel Dual Delayed Release technology, dexlansoprazole MR: a combined analysis of randomized controlled clinical trials.
Vakily M; Zhang W; Wu J; Atkinson SN; Mulford D
Curr Med Res Opin; 2009 Mar; 25(3):627-38. PubMed ID: 19232037
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the efficiency of two different proton pump inhibitor formula in treatment of patients with atypical gastroesophageal reflux disease: a prospective randomized study.
Lin XH; Luo JC; Ting PH; Chang TE; Huang YH; Hou MC; Lee FY
J Gastroenterol Hepatol; 2020 Dec; 35(12):2096-2102. PubMed ID: 32401385
[TBL] [Abstract][Full Text] [Related]
8. A randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers.
Frelinger AL; Lee RD; Mulford DJ; Wu J; Nudurupati S; Nigam A; Brooks JK; Bhatt DL; Michelson AD
J Am Coll Cardiol; 2012 Apr; 59(14):1304-11. PubMed ID: 22464259
[TBL] [Abstract][Full Text] [Related]
9. Review article: dual delayed release formulation of dexlansoprazole MR, a novel approach to overcome the limitations of conventional single release proton pump inhibitor therapy.
Metz DC; Vakily M; Dixit T; Mulford D
Aliment Pharmacol Ther; 2009 May; 29(9):928-37. PubMed ID: 19298580
[TBL] [Abstract][Full Text] [Related]
10. Addendum: Dexlansoprazole for GERD.
Med Lett Drugs Ther; 2022 May; 64(1650):79-80. PubMed ID: 35536912
[No Abstract] [Full Text] [Related]
11. Oral esomeprazole in Japanese pediatric patients with gastric acid-related disease: Safety, efficacy, and pharmacokinetics.
Shimizu T; Nakayama Y; Ishii E; Ida S; Satou T; Tokuhara D; Arai K; Nii M; Rydholm H; Yajima T;
Pediatr Int; 2019 Jan; 61(1):87-95. PubMed ID: 30422368
[TBL] [Abstract][Full Text] [Related]
12. Dexlansoprazole in the treatment of esophagitis and gastroesophageal reflux disease.
Abel C; Desilets AR; Willett K
Ann Pharmacother; 2010 May; 44(5):871-7. PubMed ID: 20371754
[TBL] [Abstract][Full Text] [Related]
13. Clinical trial: the effects of the proton pump inhibitor dexlansoprazole MR on daytime and nighttime heartburn in patients with non-erosive reflux disease.
Fass R; Chey WD; Zakko SF; Andhivarothai N; Palmer RN; Perez MC; Atkinson SN
Aliment Pharmacol Ther; 2009 Jun; 29(12):1261-72. PubMed ID: 19392864
[TBL] [Abstract][Full Text] [Related]
14. Acid control cannot be improved with a modified-release formulation of a proton pump inhibitor compared with twice-daily dosing of the conventional formulation.
Röhss K; Wilder-Smith C; Bokelund-Singh S; Sagar M; Nagy P
Dig Dis Sci; 2010 Dec; 55(12):3423-9. PubMed ID: 20238247
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of six proton pump inhibitors as inhibitors of various human cytochromes P450: focus on cytochrome P450 2C19.
Zvyaga T; Chang SY; Chen C; Yang Z; Vuppugalla R; Hurley J; Thorndike D; Wagner A; Chimalakonda A; Rodrigues AD
Drug Metab Dispos; 2012 Sep; 40(9):1698-711. PubMed ID: 22648560
[TBL] [Abstract][Full Text] [Related]
16. Safety profile of dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed release formulation: global clinical trial experience.
Peura DA; Metz DC; Dabholkar AH; Paris MM; Yu P; Atkinson SN
Aliment Pharmacol Ther; 2009 Nov; 30(10):1010-21. PubMed ID: 19735233
[TBL] [Abstract][Full Text] [Related]
17. Dexlansoprazole for Heartburn Relief in Adolescents with Symptomatic, Nonerosive Gastro-esophageal Reflux Disease.
Gold BD; Pilmer B; Kierkuś J; Hunt B; Perez MC; Gremse D
Dig Dis Sci; 2017 Nov; 62(11):3059-3068. PubMed ID: 28916953
[TBL] [Abstract][Full Text] [Related]
18. Phase I, multicenter, randomized, open-label study evaluating the pharmacokinetics and safety profile of repeated once-daily doses of intravenous esomeprazole in children 0 to 17 years of age.
Sandström M; Davidson G; Tolia V; Sullivan JE; Långström G; Lundborg P; Brown K
Clin Ther; 2012 Aug; 34(8):1828-38. PubMed ID: 22832034
[TBL] [Abstract][Full Text] [Related]
19. The Effect of Dexlansoprazole on Gastroesophageal Reflux Disease: A Systematic Review and Meta-Analysis.
Nunes GP; Silveira TC; Marciano JVS; Dos Reis-Prado AH; Ferrisse TM; Dos Anjos EB; Fernandes MH
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38279248
[TBL] [Abstract][Full Text] [Related]
20. Dexlansoprazole MR for the management of gastroesophageal reflux disease.
Behm BW; Peura DA
Expert Rev Gastroenterol Hepatol; 2011 Aug; 5(4):439-45. PubMed ID: 21780890
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
